CytoDyn Inc
↗Vancouver, Washington
CytoDyn Inc. is a publicly traded clinical-stage oncology biotechnology company developing innovative treatments based on leronlimab, a novel humanized monoclonal antibody (IgG4) that targets the CCR5 receptor. Founded in 2002 and headquartered in Vancouver, Washington, the company is advancing leronlimab as a first-in-class therapeutic with a unique mechanism of action involving CCR5 signaling inhibition and immune checkpoint modulation. The company's lead program focuses on metastatic triple-negative breast cancer (mTNBC) and relapsed/refractory microsatellite-stable colorectal cancer (mCRC), with additional research in HIV treatment, chronic inflammation, and CNS disorders including Alzheimer's disease.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology biotech / Immunotherapy
SIZE & FINANCIALS
Employees:11-50
Revenue:Pre-commercial (no revenue)
Founded:2002
Ownership:public
Status:operating
FUNDING
Stage:Late-stage clinical
Investors:Yorkville Advisors Global LP ($30M commitment, November 2025)
STOCK
Exchange:OTCQB
Ticker:CYDY
Market Cap:$354M
PIPELINE
Stage:Phase 2 clinical
Lead Drug Stage:Phase 2
Modalities:Monoclonal antibody (mAb), CCR5 antagonist
Active Trials:2
Trial Phases:Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Cornell University (Alzheimer's disease pilot study), University of Hawaii Cancer Center (oncology research), MD Anderson Cancer Center (oncology collaboration), Pennsylvania Cancer and Regenerative Medicine Research Center
COMPETITION
Position:Emerging
Competitors:Bristol Myers Squibb, Roche, AstraZeneca, Pfizer, Regeneron, ADC Therapeutics, Genmab, Incyte +1 more
LEADERSHIP
Key Executives:
Jacob Lalezari, M.D. - Chief Executive Officer
Robert E. Hoffman - Chief Financial Officer
Richard Pestell, M.D., Ph.D. - Lead Consultant, Preclinical and Clinical Oncology
Max Lataillade, M.D. - Senior Vice President and Head of Clinical Development
Melissa Palmer, M.D. - Lead Consultant, Hepatology
Board Members:Tanya Durkee Urbach (Board Chair (Independent Director)), Stephen Simes (Director (Independent, Biotech CEO experience)), Ryan Dunlap (Director (Independent, CFO with biotech experience))
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CytoDyn Inc. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.